Balyasny Asset Management L.P. and related reporting persons filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 1,611,958 shares of common stock in Crescent Biopharma, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each of the five reporting persons disclosed beneficial ownership of 1,611,958 shares of Crescent Biopharma, Inc. common stock.
  • Percent of class: The 1,611,958 shares represent approximately 4.34% of outstanding common stock, based on 37,143,940 shares outstanding as of July 27, 2026.
  • Direct holders: Atlas Private Holdings (Cayman) Ltd. holds 670,000 shares and Atlas Diversified Master Fund, Ltd. holds 941,958 shares, with Balyasny Asset Management L.P. serving as investment manager for both.
  • Sole voting and dispositive power: Each reporting person reported sole power to vote and to dispose of all 1,611,958 shares, with zero shared voting or dispositive power.
  • Reporting persons: The five filers are Balyasny Asset Management L.P., BAM GP LLC, Balyasny Asset Management Holdings LP, Dames GP LLC, and Dmitry Balyasny, all headquartered at 444 West Lake Street, 50th Floor, Chicago, IL 60606.
  • Triggering event date: The event requiring this filing occurred on September 30, 2026.

Balyasny Asset Management's Ownership Structure in Crescent Biopharma

According to the filing, Balyasny Asset Management L.P. ("BAM"), a Delaware limited partnership, acts as investment manager for two Cayman Islands exempted companies: Atlas Private Holdings (Cayman) Ltd. ("APHC"), the direct holder of 670,000 shares, and Atlas Diversified Master Fund, Ltd. ("ADMF"), the direct holder of 941,958 shares. By virtue of this investment management role, BAM is deemed to exercise voting and investment power over all 1,611,958 shares combined.

The filing describes a chain of control running through the reporting entities. BAM GP LLC is the General Partner of BAM; Balyasny Asset Management Holdings LP is the Sole Member of BAM GP LLC; Dames GP LLC is the General Partner of Balyasny Asset Management Holdings LP; and Dmitry Balyasny is the Managing Member of Dames GP LLC. The filing states that each entity in this chain may be deemed to beneficially own the same 1,611,958 shares held directly by ADMF and APHC, with each reporting person holding sole power to vote and dispose of those shares and no shared power in either respect.

The 4.34% ownership figure is calculated against 37,143,940 shares of common stock outstanding as of July 27, 2026, as reported in Crescent Biopharma's Quarterly Report on Form 10-Q filed with the SEC on July 30, 2026, according to the filing. The filing also notes under Item 5 that the aggregate ownership represents 5 percent or less of the class. ADMF and APHC are identified as the persons with the right to receive dividends from, or the proceeds from the sale of, the reported securities.

What Was Disclosed

Balyasny Asset Management L.P. and four affiliated entities and individuals filed Amendment No. 2 to a Schedule 13G reporting combined beneficial ownership of 1,611,958 shares, or approximately 4.34%, of Crescent Biopharma, Inc. common stock as of September 30, 2026.